Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 7/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 7/20 | 0.45 |
| ▸ | CETP | P11597 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140138 | 0.86 | SLC5A1 (0.42) | SLC5A1SLC5A2CETP | |
| SCHEMBL20139476 | 0.85 | SLC5A1 (0.43) | SLC5A1SLC5A2CETP | |
| SCHEMBL20140227 | 0.82 | SLC5A1 (0.53) | SLC5A1SLC5A2CETPMAPK1HTR2A | |
| SCHEMBL20139411 | 0.79 | CHRNA7 (0.47) | SLC5A1SLC5A2HTR2AHTR2C | |
| SCHEMBL20139469 | 0.75 | SLC5A1 (0.51) | SLC5A1SLC5A2CETPKDM4EALDH1A1 | |
| SCHEMBL20140145 | 0.73 | PDE10A (0.41) | SLC5A1SLC5A2MAPK1HTR2AHTR2C | |
| SCHEMBL20139929 | 0.73 | SLC5A2 (0.84) | SLC5A1SLC5A2 | |
| SCHEMBL16682942 | 0.72 | SNCA (0.47) | SLC5A1SLC5A2CETP | |
| SCHEMBL20139974 | 0.71 | TOP2A (0.36) | HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL20140087 | 0.71 | MAPK1 (0.39) | SLC5A1SLC5A2MAPK1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| WO-2018089449-A1 | BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | SLC5A1 2/4885SLC5A2 1/4885CETP 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.